
Sign up to save your podcasts
Or


Concert Pharmaceuticals’ stock rises 80% on a deal with Vertex. Jason Moser analyzes the pharmaceutical landscape and weighs in on The New York Times’ new Twitter strategy. Plus we dip into the Fool Mailbag and share memories of the late Paul Kangas.
By The Motley Fool4.7
16041,604 ratings
Concert Pharmaceuticals’ stock rises 80% on a deal with Vertex. Jason Moser analyzes the pharmaceutical landscape and weighs in on The New York Times’ new Twitter strategy. Plus we dip into the Fool Mailbag and share memories of the late Paul Kangas.

3,241 Listeners

1,499 Listeners

806 Listeners

941 Listeners

529 Listeners

1,188 Listeners

2,183 Listeners

825 Listeners

1,428 Listeners

1,054 Listeners

9,715 Listeners

194 Listeners

829 Listeners

84 Listeners

50 Listeners

1,030 Listeners

49 Listeners